Prostate Cancer: Page 4

Artemis signs $250M deal for liquid biopsy tests with Datar

By LabPulse.com staff writers

The contract gives Artemis DNA the exclusivity to commercialize and distribute the liquid biopsy tests Trucheck Pragma and Cancertrack in the U.S. and Vietnam. Trucheck Pragma is a noninvasive blood-based screening test for lung, stomach, colon, pancreas, prostate, breast, and ovarian cancers; Cancertrack is a cancer monitoring test that allows patients to evaluate response/resistance during treatment and monitor recurrence of cancer.

May 15, 2022

Paige gets nod in Europe for prostate biomarker suite

By LabPulse.com staff writers

The AI software is designed to detect the presence of four prostate cancer biomarkers on digitized tissue images stained with hematoxylin and eosin (H&E).

May 11, 2022

Cleveland Diagnostics' IsoPSA gets NCCN prostate cancer listing

By LabPulse.com staff writers

The guidelines now suggest use of IsoPSA to categorize probability of high-grade prostate cancer (i.e., Gleason score equal to or greater than 3+4, and group grade of 2 or higher) before a first biopsy or after a negative biopsy, the company said.

May 10, 2022

Accounting for genetic factors may improve PSA testing

By LabPulse.com staff writers

Presenter Linda Kachuri, PhD, of the University of California, San Francisco, and colleagues investigated whether particular genetic factors could cause variations in PSA levels that are not due to cancer, and whether accounting for these could improve PSA testing. They conducted a study that included 95,000 men with diagnosed prostate cancer from cohorts in the U.S., the U.K., and Sweden and identified 128 PSA-associated variants they used to "build a polygenic score for PSA levels."

April 10, 2022

MiR Scientific, Leonie Hill to partner on prostate cancer test

By LabPulse.com staff writers

The test uses a single urine sample to identify prostate cancer and classify disease severity, according to miR Scientific. Its technology is based on analyzing small noncoding RNAs taken from urinary exosomes; clinical studies have shown that it can find and categorize clinically significant prostate cancer with more than 90% accuracy, the company said.

March 27, 2022

Lunaphore, MGH collaborate on IVD work for solid tumors

By LabPulse.com staff writers

The collaboration will focus on ovarian, breast, and prostate cancers. The two entities will work together to develop a multiplexed immunofluorescence assay that will measure multiple protein expression.

February 17, 2022

Datar secures FDA breakthrough nod for prostate cancer test

By LabPulse.com staff writers

TriNetra-Prostate identifies early-stage prostate cancer in men between the ages of 55 and 69 with more than 99% accuracy, the company said. It requires 5 ml of blood and is indicated for men with a serum prostate-specific antigen (PSA) measure of 3 ng/mL or higher, according to Datar.

February 13, 2022

Veracyte to highlight new Decipher data at ASCO meeting

By LabPulse.com staff writers

The abstracts report results from a phase III study that evaluated the Decipher genomic classifier as a prognostic biomarker for patients diagnosed with intermediate-risk prostate cancer from diagnostic biopsy specimens, Veracyte said.

January 30, 2022

Paige AI software gets U.K. medtech innovation evaluation

By LabPulse.com staff writers

MIBs are intended to support the U.K.'s National Health Service (NHS) facilities when they are considering the use of new medical devices, Paige said. This MIB is the first for a digital pathology product, according to the firm.

December 5, 2021

Deep Bio, Tribun collaborate on AI-based digital pathology

By LabPulse.com staff writers

DeepDx, Deep Bio's deep learning-based prostate cancer diagnostic support software, will be integrated with CaloPix, part of the Tribun Health Platform. Using CaloPix, pathologists can now leverage automated prostate cancer image analysis using AI, Deep Bio said.

November 30, 2021

AI of pathology slides improves prostate cancer diagnosis

By Joseph Constance

The study suggests that AI has the potential to transform histopathological evaluation and optimize the risk stratification and clinical management of prostate cancer, giving it more of a precision approach, according to the study's authors, from the University of Wisconsin and elsewhere.

November 3, 2021

Immunis.AI touts results from prostate liquid biopsy study

By LabPulse.com staff writers

Immunis.AI's Intelligentia platform also can stratify the risk in men considering active surveillance of prostate cancer, according to the results published in Cells. (Cells, September 28, 2021, Vol. 10, pp. 2567.)

October 12, 2021

Previous Page

Page 4 of 8

Next Page